Skip to main content

Stroke

Featured Article
Deepak L. Bhatt MD, MPH, FACC, FAHA, FSCAI, FESC, executive director of Interventional Cardiovascular Programs at Brigham and Women’s Hospital Heart…
Mandeep S Randhawa, MD, division of cardiology, Michigan State University, discusses his recent study and explains why warfarin provides no benefit for ischemic stroke incidence or mortality, as well…

Insights

“While it’s important for health care systems to implement protocols that mitigate risk of virus transmission and to devote the time, attention, and resources necessary to fighting the pandemic, we can’t overlook the impact of the pandemic on…
Deepak L. Bhatt MD, MPH, FACC, FAHA, FSCAI, FESC, executive director of Interventional Cardiovascular Programs at Brigham and Women’s Hospital Heart…
Mandeep S Randhawa, MD, division of cardiology, Michigan State University, discusses his recent study and explains why warfarin provides no benefit for ischemic stroke incidence or mortality, as well as increase the risk of hemorrhagic stroke.
Konark Malhotra, MD explains what pharmacists should do if they assist patients who are prescribed both thienopyridines and proton pump inhibitors. 

Interactive Features

A recent study examined Pradaxa compared to warfarin and Xarelto for prevention of stroke and bleed-related hospitalization and costs.
A recent study analyzed over 140,000 older adults to determine the effectiveness of various anticoagulants. 
A recent study examined patients with atrial fibrillation to determine when aspirin should be used for preventing strokes.
Which of the following has not been proven to reduce the risks of onset and recurrent atrial fibrillation?
Back to Top